PolyTherics is granted a further patent for its TheraPEG PEGylation technology
PolyTherics has successfully applied its TheraPEG™ technology to a range of proteins and peptides, including interferons, blood factors and a variety of antibody formats. The latter include antibody fragments (Fabs), single chain antibodies (scFv) and novel entities such as MacroGenics’ Dual-Affinity Re-Targeting molecules (DART™). Nuron Biotech Inc has recently announced an exclusive option and license agreement with PolyTherics to use TheraPEG™ to develop NU400, a long-acting version of its proprietary recombinant human interferon beta-1b, which could enter the clinic in 2012 for the treatment of multiple sclerosis.
John Burt, CEO of PolyTherics commented: “We are pleased that our TheraPEG™ patent estate has been further extended in the US with this second US patent, which strengthens our position in offering a solution for proteins and peptides in need of half-life extension. Licensees of PolyTherics’ TheraPEG™ technology will enjoy the benefit of the additional patent protection for their products developed using the TheraPEG™ technology”.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.